1. In Vivo
  2. >>Leadership
  3. >>C-Suite Speaks

Bayer’s BD And Licensing Strategy Key To Moving Through Difficult Period

 
• By David Wild

As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience. 

Handshake of businessmen

Head of pharmaceuticals research and development, Christian Rommel, phrased it to sister publication Scrip at the J.P. Morgan Healthcare conference as the company going through a “resilience phase.” Also see "Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs" - Scrip, 18 January, 2024.

And with all hands on deck, Juergen Eckhardt, head of Bayer AG’s pharmaceuticals business development and licensing/open innovation, will need to continue his division’s winning streak, as one of Bayer’s most successful pharma partnerships winds down. Specifically, Bayer’s nearly 20-year partnership with J&J for the co-development and co-commercialization of Xarelto (rivaroxaban), which saw sales of the direct oral anticoagulant reached $6

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 
• By Urtė Fultinavičiūtė

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from Leadership

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 
• By Urtė Fultinavičiūtė

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.